EXECUTIVE LEADERSHIP SERIES: CEO HOPES TO DEVELOP NOVEL CANCER DRUG—AND RECRUIT NEW TEAM MEMBERS Posted on May 12, 2023, in News, Press Releases Read more
Grid Therapeutics Initiates a Phase 2 Investigator-Sponsored Trial of GT103 in Combination with Merck’s Pembrolizumab in Patients with Advanced Stage Non-Small Cell Lung Cancer Posted on February 27, 2023February 27, 2023, in News, Press Releases Read more
2022 Distinguished Service Awards Presented Posted on August 8, 2022, in News, Press Releases Read more
Homegrown Immunotherapy Trialed in Lung Cancer Posted on December 16, 2020December 16, 2020, in News, Press Releases Read more
Tumour extracellular vesicle‐derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement‐dependent cytotoxicity of tumour cells Posted on November 30, 2020, in News, Press Releases Read more
Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients Posted on June 24, 2020, in News, Press Releases Read more
Grid Therapeutics Announces FDA Approval of IND Application for GT103 Posted on April 15, 2020, in News, Press Releases Read more
Grid Therapeutics Closes Series B Financing Posted on April 26, 2018April 26, 2018, in News, Press Releases Read more
Grid Therapeutics Selected by the NCI’s NExT Program to Complete the IND Enabling Nonclinical Work for GT103 Posted on October 31, 2017October 31, 2017, in News, Press Releases Read more
Grid Therapeutics Collaborates with Catalent to Develop the First Human-Derived Antibody for the Treatment of Cancer Posted on October 31, 2017, in News, Press Releases Read more
